The U.S. National Institute of Child Health and Human Development awarded Contraline, Inc. a $291,440 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to develop ADAM AIR, a non-hormonal, vas occlusive contraceptive device for men. ADAM AIR is an aerogel-based version of Contraline's previously developed ADAM hydrogel, which can be implanted into the vas deferens to block sperm flow. The ADAM AIR formulation aims to reduce manufacturing and procedural complexities, while enabling on-demand reversal of the vas occlusion. The project will conduct laboratory research, clinical trials, and further studies to characterize the safety, efficacy, and reversibility of the ADAM AIR contraceptive device. The award has a performance period from September 10, 2024 to August 31, 2025.
Generated 3/4/25, 8:38 AM